0000000000634258

AUTHOR

Thomas Rogier

0000-0001-8296-3959

showing 2 related works from this author

Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia

2020

Immune thrombocytopenia (ITP) is a rare autoimmune disease due to autoantibodies targeting platelet glycoproteins (GP). The mechanism of platelet destruction could differ depending on the specificity of antiplatelet antibodies: anti-GPIIb/IIIa antibodies lead to phagocytosis by splenic macrophages, in a Fc&gamma

IVIgPhagocytosislcsh:Medicine030204 cardiovascular system & hematologyArticle03 medical and health sciencesantiplatelet antibodies0302 clinical medicinehemic and lymphatic diseasesmedicinePlateletReceptor030304 developmental biologyAutoimmune diseasechemistry.chemical_classification0303 health sciencesbiologybusiness.industrylcsh:RAutoantibodyGeneral Medicinemedicine.diseasechemistryMechanism of actionimmune thrombocytopeniaImmunologybiology.proteinAntibodymedicine.symptomGlycoproteinbusinesscirculatory and respiratory physiologyJournal of Clinical Medicine
researchProduct

The usefulness of NEWS2 at day 7 of hospitalization in predicting COVID-19 evolution and as an early endpoint in therapeutic trials

2021

Highlights • There is a need for reliable tools to predict the evolution of hospitalized patients suffering from COVID-19 • The likelihood of unfavourable evolution for patients hospitalized for COVID-19 with a National • Early Warning Score 2 (NEWS2) below 7 at Day 7 of hospitalization is nearly non-existent • Such a score could thus be used to allow earlier discharge of the patients and as a judgement criterion in therapeutic trials

0301 basic medicineMicrobiology (medical)2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNEWS2Communicable DiseasesArticle03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineIntensive care medicineUnfavourable eventAgedbusiness.industrySARS-CoV-2COVID-19Therapeutic trialCoronavirusHospitalizationInfectious DiseasesItalySARS-CoV2businessPredictionThe Journal of Infection
researchProduct